QIAGEN Revises 2026 Outlook Amid Mixed Q1 Results

QIAGEN N.V. has announced its preliminary results for the first quarter of 2026, showing a mixed performance. The company met its adjusted diluted earnings per share (EPS) outlook, with net sales reaching $492 million, a 2% increase on a reported basis but a 1% decrease at constant exchange rates (CER) compared to its growth target. The company's growth pillars saw a 4% CER increase, highlighted by a 9% CER growth in sample technologies.

Despite these gains, QuantiFERON sales decreased by 5% CER due to reduced immigration testing in the U.S. and the Middle East. In response, QIAGEN has lowered its full-year forecast for 2026, with net sales growth expected to be between 1-2% CER and adjusted diluted EPS to be at least $2.43 CER. The company projects stronger performance in the second half of 2026, driven by new product launches and diminishing past headwinds.